Maxim raised the firm’s price target on Mesoblast (MESO) to $30 from $18 and keeps a Buy rating on the shares after the FDA approved Ryoncil as the first mesenchymal stromal cell, therapy in the United States.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO: